Abstract: A vaccine composition for preventing and/or treating porcine circovirus infection is described, which comprises an immunogenic amount of porcine circovirus type 3 antigen, an immunogenic amount of porcine circovirus type 2 antigen and a pharmaceutically acceptable carrier. The vaccine composition can not only prevent and/or treat related diseases caused by infection or mixed infection of different gene subtypes of porcine circovirus, but also have immunoprotective effects against strains of different geographical origins.
Abstract: The disclosure relates to a vaccine composition for preventing and/or treating porcine circovirus infection, which comprises an immunogenic amount of porcine circovirus type 3 antigen, an immunogenic amount of porcine circovirus type 2 antigen and a pharmaceutically acceptable carrier. The vaccine composition can not only prevent and/or treat related diseases caused by infection or mixed infection of different gene subtypes of porcine circovirus, but also have immunoprotective effects against strains of different geographical origins.
Abstract: A porcine circovirus type 3 virus strain and a vaccine composition prepared from the immunogenic substance of the strain are described. The porcine circovirus type 3 virus strain has good immunogenicity, and the prepared vaccine composition can provide complete protection against varies of porcine circovirus type 3 viruses from different sources.
Abstract: The present disclosure provides a vaccine composition comprising an immune amount of Fiber protein of egg drop syndrome virus or an immune amount of a live vector recombined with gene of the Fiber protein of egg drop syndrome virus and a veterinarily acceptable carrier.
Abstract: The present invention provides an attenuated strain of porcine pseudorabies virus (PRV), in which said attenuated strain of PRV is a variant strain of PRV with inactivation of gI/gE/11K/28K proteins. In addition, the present invention also provides a vaccine composition comprising the attenuated strain of PRV as an antigen, a preparation method and use thereof. Proved by immunogenicity and pathogenicity testing of the live vaccine, said live PRV vaccine can provide a good protection for pigs with no clinical signs observed, indicating excellent immune protection.
Type:
Grant
Filed:
January 6, 2015
Date of Patent:
February 4, 2020
Assignee:
PULIKE BIOLOGICAL ENGINEERING, INC.
Inventors:
Kegong Tian, Xuke Zhang, Jinzhong Sun, Feifei Tan
Abstract: The disclosure relates to a porcine circovirus type 3 virus strain, and a vaccine composition prepared from the immunogenic substance of the strain, the porcine circovirus type 3 virus strain has good immunogenicity, and the prepared vaccine composition can provide complete protection against varies of porcine circovirus type 3 viruses from different sources.
Abstract: The present disclosure provides a PRV gB protein fragment, or a conservative variant or active fragment thereof, the gB protein fragment has a high level of expression, the subunit vaccine antigen prepared from the gB protein fragment has a better immune effect than a subunit vaccine antigen prepared from gB protein. The invention also provides a preparation method of a subunit vaccine by using the gB protein fragment alone, or the gB protein fragment together with gD protein. This vaccine has a simple preparation method and provides excellent protection against disease caused by the porcine pseudorabies virus.
Abstract: The present invention provides an attenuated strain of porcine pseudorabies virus (PRV), in which said attenuated strain of PRV is a variant strain of PRV with inactivation of gI/gE/11K/28K proteins. In addition, the present invention also provides a vaccine composition comprising the attenuated strain of PRV as an antigen, a preparation method and use thereof. Proved by immunogenicity and pathogenicity testing of the live vaccine, said live PRV vaccine can provide a good protection for pigs with no clinical signs observed, indicating excellent immune protection.
Type:
Grant
Filed:
July 19, 2016
Date of Patent:
February 12, 2019
Assignee:
PULIKE BIOLOGICAL ENGINEERING, INC.
Inventors:
Kegong Tian, Xuke Zhang, Jinzhong Sun, Feifei Tan
Abstract: The present disclosurerelates to a vaccine composition, wherein the vaccine composition comprises an immune amount of fowl adenovirus Fiber-2 protein or an immune amount of a live vector recombined with gene of the fowl adenovirus Fiber-2 protein, and a pharmaceutically acceptable carrier. The vaccine composition can provide effective immune protection against different serotypes of adenoviruses and provide a protection rate of 100% at low levels of immunogenic components, showing good immunological efficacy.
Abstract: This invention provides a method of attenuating porcine pseudorabies virus, which can effectively and reproducibly attenuate porcine pseudorabies virus. The attenuated strain of porcine pseudorabies virus by use of said method can provide effective immunization for pigs.
Abstract: This invention provides a method of attenuating porcine pseudorabies virus, which can effectively and reproducibly attenuate porcine pseudorabies virus. The attenuated strain of porcine pseudorabies virus by use of said method can provide effective immunization for pigs.
Abstract: The present disclosure relates to a macrolide compound as shown by formula I and pharmaceutically acceptable salt thereof. The compound of the present disclosure is an antibacterial agent, and can be used to treat various bacterial and protozoal infections. The present disclosure further relates to the preparation method of the compound and a pharmaceutical composition thereof.
Abstract: Provided in the embodiments of the present invention is a vaccine composition including an immune amount of attenuated live vaccine, inactivated vaccine, subunit vaccine, synthetic vaccine, or genetically engineered vaccine of the porcine pseudorabies virus strain. The vaccine composition can effectively induce antibody generation, and prevent infections of virulent strains of the porcine pseudorabies virus, and provides effective protection for pigs.
Abstract: Provided in embodiments of the present invention is a vaccine composition including an immune amount of attenuated live vaccine, inactivated vaccine, subunit vaccine, synthetic peptide vaccine, or genetically engineered vaccine of the porcine pseudorabies virus strain. The vaccine composition can effectively induce antibody generation, and prevent infections of virulent strains of the porcine pseudorabies virus, and provides effective protection for pigs.
Abstract: Provided in the embodiments of the present invention is a vaccine composition including an immune amount of attenuated live vaccine, inactivated vaccine, subunit vaccine, synthetic vaccine, or genetically engineered vaccine of the porcine pseudorabies virus strain. The vaccine composition can effectively induce antibody generation, and prevent infections of virulent strains of the porcine pseudorabies virus, and provides effective protection for pigs.